CLL patients left in the dark: study maps treatment gaps after key drug fails

NCT ID NCT05621148

Completed Knowledge-focused Sponsor: French Innovative Leukemia Organisation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 152 adults with chronic lymphocytic leukemia (CLL) whose cancer stopped responding to a class of drugs called BTK inhibitors (like ibrutinib) and, in some cases, also to venetoclax. The goal was to understand what treatments doctors used next and how well they worked, since there is no standard approach for these patients. The study did not test a new treatment but instead collected real-world data to highlight unmet medical needs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRUTON TYROSINE KINASE INHIBITOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRUTON TYROSINE KINASE INHIBITOR CLL, REFRACTORY CLL, RELAPSED SMALL LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Bordeaux Pessac

Pessac, 33604, France
CHU Estaing - Hématologie Clinique Adulte

Clermont-Ferrand, 63000, France
Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Centre Léon Bérard - Hématologie

Lyon, 69373, France
Institut Paoli-Calmettes - Hématologie Clinique

Marseille, 13273, France
MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique

Montpellier, 34295, France
Strasbourg - Icans

Strasbourg, 67033, France
Toulouse - IUCT Oncopole - Service d'Hématologie

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.